Global Epidemiology of Pediatric Traumatic Brain Injury: Systematic Review and Meta-Analysis.

NeurosurgeryDec 12, 2025 (epub)
Clinical ResearchPediatricsNeurology

Ronnie E Baticulon, Jinno Jenkin Sy, Joseline Haizel-Cobbina et al.

✦ AI-curated · Sources linked

In 30 seconds

This systematic review and meta-analysis examined the global incidence, mortality, clinical severity, and causes of pediatric traumatic brain injury (TBI), drawing on population-level and hospital-level studies published from 2000 onward. The estimated annual incidence was 226.4 per 100 000 children, and an estimated 1.9 per 100 000 children died from TBI each year. Across hospital studies, 11.0% of patients had severe TBI and overall mortality was 1.4%. Studies from low- and middle-income countries reported higher proportions of severe TBI and higher mortality.

Key findings

  • Estimated global pediatric TBI incidence was 226.4 per 100 000 children annually; estimated annual TBI mortality was 1.9 per 100 000.
  • Across 79 studies from 42 countries, 11.0% (median: 10.7%) of patients had severe TBI; overall mortality was 1.4% (median: 3.2%).
  • In 28 studies, the median mortality rate for severe TBI was 26.7%.
  • Low- and middle-income country studies reported higher proportions of severe TBI and higher mortality; road traffic injuries predominated in Africa and low-income countries, while falls were more common elsewhere.

Why it matters

The review indicates a substantial worldwide burden of childhood TBI and highlights differences in severity, mortality, and injury causes across settings. These estimates can inform public health planning and underscore the need for better population-level data, particularly in low- and lower-middle-income countries, where the evidence base remains limited.

What to keep in mind

Population-level data were lacking in low- and lower-middle-income countries, limiting estimates and comparisons. Differences in reported incidence may reflect either true variation or differences in health-system capacity.

Source

Published in Neurosurgery. This summary was written by xxcode from the publication's abstract and metadata. It is not peer reviewed and is not a substitute for the original article. For clinical decisions, review the original publication.

ShareTelegramLinkedIn

AI-generated summaries may contain errors or omissions. Verify clinically important information with the original publication.

More in Pediatrics

Clinical ResearchOncology (Medical)

Zamtocabtagene autoleucel, a tandem CD20-CD19-directed CAR T-cell therapy, for second line treatment of large B-cell lymphoma in patients ineligible for transplantation (DALY 2-EU): primary analysis of an open-label, multicentre, randomised phase 2 study.

DALY 2-EU was an open-label, multicentre, randomised phase 2 trial comparing tandem CD20-CD19-directed zamtocabtagene autoleucel (zamto-cel) with R-GemOx in adults with second-line relapsed or refractory large B-cell…

Lancet OncolOct 27, 2026Read summary
Clinical ResearchOncology (Medical)

Neoadjuvant short-course radiotherapy followed by camrelizumab and chemotherapy versus standard of care for locally advanced rectal cancer (UNION): a prespecified interim analysis of a multicentre, open-label, randomised, phase 3 trial.

UNION was a multicentre, open-label, randomised phase 3 trial at nine hospitals in China comparing neoadjuvant short-course radiotherapy followed by camrelizumab plus CAPOX with long-course chemoradiotherapy followed by…

Lancet OncolOct 25, 2026Read summary
Clinical ResearchHematology

Efficacy and safety of mitapivat in patients with sickle cell disease (RISE UP): a phase 3, double-blind, global, randomised, placebo-controlled trial.

RISE UP was a phase 3, double-blind, global, randomised, placebo-controlled trial conducted at 69 sites in 15 countries. It evaluated twice-daily mitapivat in patients older than 16 years with sickle cell disease…

LancetOct 24, 2026Read summary

Want this personalized?

Stop searching the literature. Choose what you follow and xxcode will build your personalized medical digest.

  • Your specialties
  • Your filters and thresholds
  • Clinical Research + Case Reports, tuned separately
  • Automatic weekly delivery
  • Audio and text

Prefer listening? Personalized audio digests are available with Pro.

Stay updated for free

Get the 3 most interesting publications in one specialty each week.

Weekly email. Unsubscribe anytime.